JimTash.. He already knows...Once the proposed merger according to the 2010 LOI,between radient and provista along with their subsidiry GCDX he will do the honors you understand...What was the name of that company you claim is buying the radient shell? And we should deflect our resources to... It is in Taiwan and you found it in your DD and posted it here last month..it starts with an A...? tia wolfie imololooololoooooooooooooooo
livinginsv Thursday, 03/26/15 11:12:32 AM Re: guardiangel post# 28514 Post # of 28516
tell reese you ADDED to HIS pipeline . . .
maybe you can offer to fix his website to show the same . .
livinginsv Thursday, 03/26/15 11:12:32 AM Re: guardiangel post# 28514 Post # of 28518
tell reese you ADDED to HIS pipeline . . .
Latest March 9, 2015 Provista Diagnostics presented data from key clinical studies utilizing a proprietary novel blood-based combinatorial biomarker assay at The 2015 Miami Breast Cancer Conference®, held February 26 – March 1, 2015 in Miami, Florida. December 10, 2014 Provista Diagnostics to Present Data from a Prospective Clinical Trial at the 2014 San Antonio Breast Cancer Symposium. Data Highlights the Role of Serum Protein Biomarkers in Conjunction with Tumor Associated Autoantibodies to Distinguish Benign from Invasive Breast Lesions December 5, 2014 Provista Diagnostics’ Blood-based Diagnostic Featured in Oncology & Hematology Review. Highlights the Potential of Serum Protein Biomarkers in Conjunction with Tumor Associated Autoantibodies to Improve Early Detection of Breast Cancer in conjunction with standard imaging practices November 10, 2014 Provista Diagnostics Accepted for a Late-Breaking Data Presentation at the 2014 San Antonio Breast Cancer Symposium: Data Explores the Ability of Serum Protein Biomarkers in Conjunction with Tumor Associated Autoantibodies to Distinguish Between Benign and Invasive Breast Lesions September 26, 2014 Provista Diagnostics to Participate in BTIG’s Inaugural Emergin Technologies in Healthcare Diagnostics Symposium September 9, 2014 ASCO: Provista's autoantibody/biomarker combo boosts breast cancer screening accuracy September 9, 2014 Provista Diagnostics, Inc. to Present at Rodman & Renshaw Annual Global Investment Conference September 8, 2014 Provista Diagnostics Announces Key Data Presented at the American Society of Clinical Oncologist Breast 2014 Annual Meeting: Data Demonstrates the Ability of Serum Protein Biomarkers in Conjunction with Autoantibodies to Distinguish Between Invasive Breast Cancer and Benign Breast Conditions August 18, 2014 Provista Diagnostics, Inc. Joins Personalized Medicine Coalition (PMC) July 15, 2014 Provista Diagnostics Completes Enrollment of its 001 Prospective Study of Protein-Based Biomarker Blood Test to Aid in Detection of Breast Cancer Prospective, Randomized, Multi-Center Study For Breast Cancer Detection in 351 Female Patients with Suspicious Breast Lesions July 7, 2014 Provista Diagnostics, Inc. Appoints Rao V. Mulpuri, PhD, MBA, as Chief Operating Officer June 26, 2014 Provista Diagnostics Laboratory Receives Accreditation from College of American Pathologists (CAP) June 7, 2014 Provista Diagnostics, Inc. Joins AdvaMed Dx May 27, 2014 Provista Diagnostics Expands Exclusive License Agreement for Biomarker Technologies Developed at the Biodesign Institute at Arizona State University May 19, 2014 Provista Diagnostics Announces First Patient Enrolled in Prospective, Proof-of-Concept Study of its Protein Biomarker Blood Test to Assess Presence of Breast Cancer April 25, 2014 Provista Diagnostics Secures $6MM Series B Financing March 3, 2014 Initiated new 500 patient Clinical Trial - 002 in breast cancer for women ages 25-75